lead
caus
liver
cirrhosi
hepatocellular
carcinoma
hcc
hepat
b
viru
hbv
chronic
infect
one
major
public
health
problem
worldwid
current
interferon
nucleosid
analog
na
lamivudin
telbivudin
entecavir
wide
use
antihbv
therapi
howev
none
perfect
na
target
viral
polymeras
suppress
hbv
viral
replic
long
term
treatment
may
result
develop
drugresist
mutant
therapi
advantag
finit
treatment
durat
absenc
drug
resist
higher
rate
hepat
b
surfac
antigen
hbsag
hepat
b
e
antigen
hbeag
seroconvers
disadvantag
great
side
effect
also
obviou
therefor
screen
develop
new
drug
potent
antihbv
activ
low
toxic
novel
mode
action
undoubtedli
essenti
combat
chronic
hbv
infect
life
cycl
hbv
viral
genom
transcrib
produc
kb
viral
mrna
among
pgrna
encod
polymeras
core
protein
also
act
templat
hbv
dna
replic
intermedi
synthesi
insid
nucleocapsid
previou
work
show
synthesi
hbv
mrna
govern
liver
enrich
transcript
factor
hepatocyt
nuclear
factor
farnesoid
x
receptor
peroxisom
proliferatoractiv
receptor
ppar
retinoid
x
receptor
ccaatenhanc
bind
protein
cebp
among
transcript
factor
shown
play
central
role
hbv
transcript
especi
gener
pgrna
member
nuclear
receptor
superfamili
control
much
liver
gene
express
sinc
discoveri
earli
well
character
wide
associ
divers
group
cellular
function
includ
carbohydr
lipid
amino
acid
metabol
differenti
inflamm
morphogenesi
immun
respons
addit
multipl
known
function
evidenc
contribut
mani
patholog
develop
includ
inflammatori
bowel
diseas
cancer
chronic
hbv
infect
liver
biopsi
specimen
collect
chronic
hbv
infect
patient
posit
correl
express
hbv
replic
sampl
higher
express
contain
higher
level
hbv
dna
moreov
overexpress
cell
increas
pgrna
synthesi
knockdown
specif
short
hairpin
rna
decreas
pgrna
express
cell
mice
liver
suggest
may
function
promis
drug
target
antipersist
hbv
infect
chines
herb
radix
bupleuri
repres
one
import
herbal
drug
asia
wide
use
treat
fever
malaria
influenza
hepat
diseas
eurasia
north
africa
mani
asian
countri
recent
decad
mani
valuabl
biolog
activ
radix
bupleuri
identifi
antitumor
antiinflammatori
antidepress
immunomodulatori
hepatoprotect
antivir
develop
modern
pharmacolog
compound
isol
radix
bupleuri
among
saikosaponin
ssa
saikosaponin
saikosaponin
c
ssc
saikosaponin
ssd
consid
major
bioactiv
constitu
although
three
sakosaponin
ssa
ssc
ssd
share
basal
structur
biolog
activ
alway
exampl
ssa
ssd
well
document
antiinflammatori
activ
wherea
littl
report
ssc
inflamm
regulatori
role
addit
among
four
major
bioactiv
compon
radix
bupleuri
ssc
saikosaponin
identifi
exhibit
antihbv
replic
activ
interestingli
unlik
ssd
stimul
mitochondri
apoptosi
hepatocyt
exhibit
hepatotox
ssc
exert
antiapoptot
effect
primari
human
umbil
vein
endotheli
cell
huvec
cell
therefor
ssc
appear
promis
therapeut
candid
chronic
hbv
infect
despit
great
progress
mechan
ssc
act
inhibit
hbv
replic
remain
unknown
studi
investig
antihbv
activ
ssc
stabli
express
hbv
cell
line
provid
evid
ssc
attenu
pgrna
synthesi
stimul
express
attenu
express
ssc
j
k
scientif
catalogu
dimethyl
sulfoxid
catalogu
catalogu
sigma
human
hepatoma
cell
line
cultur
tissu
cultur
dish
dmem
medium
contain
fb
gibco
unitml
penicillin
streptomycin
hyclon
glutamin
effect
ssc
cell
growth
determin
use
cell
count
assay
transgen
biotech
microtit
plate
total
volum
cell
densiti
cellswel
treat
ssc
mgml
dmso
vv
h
replac
drugfre
medium
cell
count
assay
carri
use
manufactur
instruct
coreassoci
hbv
dna
extract
describ
minor
modif
briefli
buffer
mm
nacl
ad
cellular
lysat
supernat
cell
volum
ratio
mixtur
shaken
slowli
overnight
centrifug
min
centrifug
eppendorf
germani
pegprecipit
pellet
digest
dnase
takara
proceed
dna
extract
hbv
dna
isol
use
qiamp
dna
blood
mini
kit
qiagen
accord
manufactur
instruct
primer
use
detect
hbv
dna
follow
f
gtg
gat
tcg
cac
tcc
r
ttc
ttc
ttc
tag
ggg
acc
total
pcr
mixtur
contain
forward
primer
revers
primer
sybr
pcr
mix
takara
rox
hbv
dna
prepar
realtim
pcr
assay
thermocycl
condit
hot
start
min
cycl
follow
cycl
easypur
viral
rna
kit
transgen
biotech
use
rna
extract
isol
hbv
rna
revers
transcrib
use
master
mix
takara
random
primer
revers
transcript
carri
manufactur
instruct
quantif
hbv
dna
perform
abi
realtim
pcr
system
primer
detect
hbv
kbpgrna
describ
previous
primer
use
detect
hbv
kb
rna
follow
f
gac
cat
caa
atg
r
ctc
aga
ccg
tag
cac
acg
aca
primer
use
detect
hbv
total
rna
follow
f
cca
gca
cca
tgc
r
cca
ccc
aag
gca
primer
use
detect
follow
tgg
gcc
aag
tac
ttt
gag
gta
ggc
gcg
cta
tgg
aca
ttg
gtg
aac
gta
primer
specif
gapdh
intern
control
follow
f
tcc
acc
cat
ggc
aaa
ttc
r
tga
tgg
gat
cat
tga
realtim
pcr
reaction
mixtur
contain
forward
primer
revers
primer
sybr
pcr
mix
takara
rox
cdna
thermocycl
condit
hot
start
min
cycl
follow
cycl
level
hbsag
hbeag
cultur
medium
measur
commerci
enzym
link
immunosorb
kit
hbsag
kit
abnova
hbeag
kit
abnova
respect
sampl
examin
triplic
result
present
fold
chang
neg
control
normal
luciferas
activ
hbv
cccdna
purif
quantif
carri
describ
previous
slight
modif
detail
total
dna
extract
either
cell
cell
treat
h
u
plasmidsaf
atp
depend
dnase
psad
epicentr
digest
singlestrand
dna
linear
doublestrand
dna
psad
digest
carri
use
reaction
volum
contain
psad
buffer
mm
atp
takara
psad
deioniz
water
total
dna
digest
sampl
purifi
qiaamp
dna
blood
mini
kit
qiagen
resuspend
steril
water
quantifi
hbv
cccdna
specif
primer
target
hbv
dna
gap
region
fluoresc
hybrid
probe
use
sequenc
primer
probe
follow
hbv
cccdnaf
ctg
tgc
ctt
ctc
atc
nt
hbv
cccdnar
cag
ctt
gga
ggc
ttg
nt
hbv
cccdnaprob
tag
gca
taa
att
ggt
ctg
cga
hbv
cccdna
amplifi
use
abi
realtim
pcr
system
follow
amplif
profil
initi
denatur
cycl
min
follow
cycl
denatur
anneal
final
incub
min
plasmid
use
gener
standard
curv
quantif
whole
cell
extract
prepar
icecold
ripa
buffer
beyotim
follow
bradford
protein
determin
use
biorad
protein
assay
kit
biorad
protein
separ
sdspage
transfer
pvdf
membran
amersham
bioscienc
usa
hybrid
cst
anti
cst
protientech
antigapdh
cst
antihbcag
abcam
antibodi
incub
horseradish
peroxidaseconjug
secondari
antibodi
protientech
immunoblot
visual
chemilluminesc
beyotim
lamivudineresist
plu
telbivudineresist
entecavirresist
plu
plu
construct
alter
wildtyp
plasmid
substitut
fragment
hbv
polymeras
gene
mutant
one
detail
fragment
contain
mutat
amplifi
pcr
purifi
gel
extract
kit
digest
two
restrict
endonucleas
hindiii
xhoi
plasmid
digest
two
restrict
endonucleas
hindiii
xhoi
ligat
construct
verifi
dna
sequenc
amplif
four
primer
use
nyf
ttc
tga
cta
ctg
cct
aac
tga
gcc
atg
aga
aac
pair
gener
atg
gct
cag
ttt
act
agt
nyr
gct
cta
ata
cga
ctc
pair
gener
fragment
fragment
fragment
purifi
gel
extract
kit
respect
get
fragment
mutat
third
round
pcr
perform
fragment
fragment
templat
nyf
nyr
primer
use
sequenc
confirm
mutant
templat
primer
specif
lamivudineresist
plu
telbivudineresist
entecavirresist
plu
plu
mutant
construct
respect
amplif
four
primer
includ
nyf
nfr
two
primer
use
aac
tga
gcc
atg
aga
aac
atg
gct
cag
ttt
act
agt
amplif
four
primer
use
follow
nyf
nfr
tcg
gtt
atg
tgg
atg
atg
tgg
tat
vr
atc
cac
ata
acc
gaa
agc
caa
aca
two
small
interf
rna
specif
target
purchas
thermo
fisher
scientif
knockdown
effect
sirna
measur
western
blot
assay
nonspecif
sirna
target
replicas
region
sever
acut
respiratori
syndrom
sar
coronaviru
genom
sisar
gca
cuu
guc
uac
cuu
gau
homolog
hbv
human
genom
use
neg
control
part
studi
first
examin
cytotox
ssc
assay
experi
ssc
show
toxic
either
cell
fig
consist
previou
studi
ssc
nontox
cell
fulli
evalu
antihbv
activ
ssc
determin
hbv
dna
replic
pgrna
synthesi
antigen
hbsag
hbeag
express
cell
fig
show
incub
cell
ssc
h
decreas
intracellular
hbv
dna
supernat
hbv
dna
confirm
result
hbsag
hbeag
examin
commerci
avail
elisa
kit
fig
show
respons
ssc
treatment
hbeag
express
decreas
hbsag
decreas
observ
interestingli
found
ssc
treatment
suppress
hbv
pgrna
synthesi
dose
depend
manner
fig
mention
previou
work
addit
pgrna
hbv
cccdna
also
examin
investig
step
hbv
life
cycl
affect
ssc
show
fig
although
intracellular
pgrna
decreas
ssc
treatment
hbv
cccdna
remain
stabl
seem
transcript
cccdna
mrna
interrupt
ssc
determin
function
ssc
quantifi
hbv
total
mrna
hbcag
express
cell
show
fig
f
addit
ssc
result
decreas
hbv
total
rna
hbcag
previou
work
show
hepatocyt
enrich
transcript
factor
determin
pgrna
synthesi
concert
action
hepatocyt
evalu
whether
play
role
ssc
mediat
pgrna
suppress
compar
express
cell
fig
show
express
increas
tremend
hbv
produc
cell
confirm
result
express
cell
transfect
either
pegfp
phbv
plasmid
analyz
western
blot
compar
control
express
increas
significantli
phbv
transfect
cell
testifi
strong
link
two
molecul
hbv
infect
fig
examin
express
cell
presenc
ssc
compar
control
ssc
treatment
significantli
inhibit
express
fig
previou
work
suggest
bind
enhanc
region
hbv
play
critic
role
regul
hbv
transcript
knock
respect
small
sirna
compar
pgrna
express
presenc
absenc
ssc
present
antihbv
activ
ssc
greatli
attenu
either
knock
fig
demonstr
play
import
role
ssc
mediat
pgrna
transcript
extracellular
signal
cytokin
affect
hbv
transcript
dysregul
liverenrich
transcript
factor
previous
cytokin
includ
found
control
express
differ
signal
pathway
identifi
cytokin
involv
ssc
mediat
antihbv
signal
pathway
cell
treat
ssc
h
mrna
extract
qpcr
assay
fig
b
show
addit
ssc
significantli
stimul
express
instead
cytokin
affect
activ
jun
ntermin
kinas
jnk
jnk
phosphoryl
control
express
test
jnk
phosphoryl
ssc
incub
cell
found
ssc
significantli
enhanc
jnk
phosphoryl
fig
detail
analysi
effect
pgrna
treat
cell
recombin
thermo
fisher
scientif
fig
e
show
express
pgrna
significantli
decreas
respons
ssc
treatment
consist
previou
studi
target
nuclear
cccdna
minichromosom
inhibit
cccdna
transcript
measur
ssc
activ
drugresist
hbv
mutant
construct
three
plasmid
harbor
hbv
genom
dna
respect
mutat
lamivudineresist
mutant
plu
telbivudineresist
mutant
entecavirresist
mutant
plu
plu
examin
antihbv
activ
ssc
three
mutant
show
fig
ssc
exhibit
signific
antihbv
activ
three
nucleosideresist
mutant
inhibit
efficaci
ssc
three
drugresist
hbv
mutant
similar
wildtyp
one
demonstr
ssc
effect
drugresist
hbv
mutant
although
advent
nucleosid
analog
make
signific
progress
manag
hbv
infect
chronic
hbv
carrier
requir
longterm
antivir
treatment
challeng
clinic
therapi
substanti
urgent
need
search
novel
drug
address
issu
avail
drug
resist
viru
rebound
natur
product
especi
chines
herbal
medicin
chm
import
sourc
new
drug
last
year
chm
wide
use
treatment
hbv
carrier
herb
includ
radix
astragali
radix
salvia
miltiorrhiza
radix
bupleuri
prove
effect
term
serorevers
hbsag
hbeag
hbv
dna
recent
number
natur
compound
chm
block
hbv
replic
identifi
includ
curcumin
wogonin
ellag
acid
artemisinin
artesun
chrysophanol
ssc
asiaticosid
helioxanthin
oxymatrin
studi
investig
antihbv
activ
ssc
one
saikosaponin
extract
medicin
plant
radix
bupleuri
present
ssc
significantli
suppress
pgrna
synthesi
show
littl
sign
toxic
cell
consist
previou
studi
found
ssc
inhibit
apoptosi
promot
us
search
potenti
intracellular
target
ssc
control
hbv
level
transcript
regul
precis
recruit
host
factor
cccdna
demonstr
studi
ssc
significantli
suppress
express
effect
cebp
cccdna
supplementari
fig
fig
suggest
ssc
regul
pgrna
transcript
global
regul
gene
express
gener
involv
inflamm
process
occur
liver
extracellular
proinflammatori
cytokin
includ
prove
inhibit
pgrna
transcript
dysregul
express
question
whether
ssc
could
regul
extracellular
cytokin
express
hbv
replic
cell
data
show
express
upregul
ssc
incub
cell
howev
sign
promot
observ
cell
without
hbv
infect
supplementari
fig
seem
ssc
stimul
express
liver
cell
specif
relat
hbv
infect
consist
find
ssc
act
proinflammatori
molecular
kougi
shyu
et
al
found
ssc
bore
properti
induc
endotheli
cell
migrat
activ
mitogenactiv
protein
kinas
mapk
extracellular
matrixregul
kinas
erk
contrast
saikosaponin
ssa
ssd
prove
possess
antiinflammatori
activ
exampl
ssa
exert
antiinflammatori
activ
inhibit
express
proinflammatori
cytokin
regul
inflammationassoci
signal
pathway
mapk
pathway
nuclear
pathway
addit
inflamm
contrari
role
differ
saikosaponin
signal
pathway
also
frequent
observ
kyo
et
al
found
ssd
stimul
prostaglandin
releas
periton
macrophag
rat
glioma
cell
ssa
ssc
inhibitori
observ
saikosaponin
ssa
ssc
ssd
share
basal
structur
side
chain
group
differ
structur
ssa
ssd
contain
disaccharid
glucosefucos
howev
ssc
contain
trisaccharid
specul
differenti
present
function
saikosapoin
may
attribut
differ
side
chain
specif
determin
target
bind
protein
interact
metabol
addit
find
still
lot
interest
point
worth
studi
previou
studi
cancer
treatment
suggest
saikosaponin
ssa
ssb
ssc
ssd
potent
adjuv
abl
overrid
primari
drug
resist
improv
sensit
chemotherapi
radiotherapi
enhanc
livertarget
effect
anticanc
drug
chronic
hbv
therapi
variou
drug
combin
therapi
tri
combin
therapi
offer
sever
advantag
singl
drug
therapi
found
necessari
chronic
hbv
infect
exampl
rapid
achiev
undetect
hbv
dna
level
increas
rate
seroconvers
hepat
b
e
antigen
seem
select
adjuv
import
chronic
hbv
combin
therapi
observ
ssc
show
cytotox
effect
wildtyp
drugresist
hbv
strain
featur
make
potent
choic
combin
drug
current
use
clinic
therapi
despit
mani
advantag
ssc
found
issu
ssc
antihbv
activ
still
unsolv
exampl
studi
tajiri
h
et
al
show
prescript
xiaochaihutang
promot
clearanc
hbeag
children
chronic
hbv
infect
toxic
radix
bupleuri
also
observ
although
ssc
prove
effect
antihbv
activ
littl
toxic
conclus
summar
base
vitro
experi
investig
effect
mechan
ssc
activ
hbv
relat
studi
vivo
anim
carri
near
futur
